Extramotor involvement in ALS: PET studies with the GABAA ligand [11C]flumazenil
about
Widespread structural and functional connectivity changes in amyotrophic lateral sclerosis: insights from advanced neuroimaging researchAmyotrophic lateral sclerosis: considerations on diagnostic criteriaGamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron diseaseWhat does imaging reveal about the pathology of amyotrophic lateral sclerosis?Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease.Neuroimaging to investigate multisystem involvement and provide biomarkers in amyotrophic lateral sclerosisWidespread sensorimotor and frontal cortical atrophy in Amyotrophic Lateral SclerosisMultimodal assessment of white matter tracts in amyotrophic lateral sclerosis.Towards molecular imaging of multiple sclerosis.Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosisMechanisms, models and biomarkers in amyotrophic lateral sclerosisUnravelling the enigma of selective vulnerability in neurodegeneration: motor neurons resistant to degeneration in ALS show distinct gene expression characteristics and decreased susceptibility to excitotoxicity.Investigating Default Mode and Sensorimotor Network Connectivity in Amyotrophic Lateral Sclerosis.Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?Reduced NAA in motor and non-motor brain regions in amyotrophic lateral sclerosis: a cross-sectional and longitudinal study.The cognitive profile of amyotrophic lateral sclerosis: A meta-analysis.Altered cortical beta-band oscillations reflect motor system degeneration in amyotrophic lateral sclerosis.Voxel-based mapping of grey matter volume and glucose metabolism profiles in amyotrophic lateral sclerosis.Calretinin and Neuropeptide Y interneurons are differentially altered in the motor cortex of the SOD1G93A mouse model of ALS.NO orchestrates the loss of synaptic boutons from adult "sick" motoneurons: modeling a molecular mechanism.Inhibitory dysfunction in amyotrophic lateral sclerosis: future therapeutic opportunities.Impairments in Motor Neurons, Interneurons and Astrocytes Contribute to Hyperexcitability in ALS: Underlying Mechanisms and Paths to Therapy.Further development of biomarkers in amyotrophic lateral sclerosis.Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis.Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis.Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks.Role of PET and SPECT in the study of amyotrophic lateral sclerosis.Neuroimaging of motor neuron diseases.Metabolic spatial connectivity in amyotrophic lateral sclerosis as revealed by independent component analysis.EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases.Distribution of GABAA receptor mRNA in the motor cortex of ALS patients.Cortical selective vulnerability in motor neuron disease: a morphometric study.Motoneuron Disease: Clinical.Combined structural and neurochemical evaluation of the corticospinal tract in amyotrophic lateral sclerosis.Neuronal loss associated with cognitive performance in amyotrophic lateral sclerosis: an (11C)-flumazenil PET study.Comparison of plasma input and reference tissue models for analysing [(11)C]flumazenil studies.Etiogenic factors present in the cerebrospinal fluid from amyotrophic lateral sclerosis patients induce predominantly pro-inflammatory responses in microglia.Brain perfusion imaging in amyotrophic lateral sclerosis: extent of cortical changes according to the severity and topography of motor impairment.DHPLC can be used to detect low-level mutations in amyotrophic lateral sclerosis.Frequency-specific alterations in the fractional amplitude of low-frequency fluctuations in amyotrophic lateral sclerosis.
P2860
Q21285058-24153BBE-941A-4AD4-82DA-B21711508D33Q22305918-7EC3C56A-1563-4A7A-832D-716A5CAA2463Q24244456-D6035CF9-A77A-4A24-BCE5-A59E9A1CF8F1Q27007017-6FB3B184-77CA-4C59-BBE8-415B737B07EDQ30239103-D34D2228-FFC7-4A3A-B484-CFA4E875A188Q30832443-D1ADDC63-EA90-4401-97D9-E67D70A2E7D9Q33241059-FD0C43B4-B384-40AB-BCBB-9BE8D002D431Q33757517-19DAEACD-5D52-46C7-BD76-768B74BDB375Q33787779-899F2DEA-599B-4046-B1FA-8C1A6343199AQ34312322-BFBC963A-C149-4D76-BB34-B0C868B5B406Q34344992-42A08F6E-86BB-4B73-8D3A-E776F72E6BEBQ34473390-331DC3C9-3AC9-4665-973C-2489CA09DBD0Q36056648-A88CBE31-46D3-407D-8A5B-5625E049D532Q36648907-1971BD32-E5FA-4CD7-B109-3FD17ED6D978Q37348418-FD5BDBC4-8A3A-48FE-87CD-45AA0ABF2735Q37380739-67F124B6-2577-41A9-AE80-73E4CB074FB3Q37561488-6019A51B-2F06-4E9E-B4CF-50DD83AE0A24Q37683109-82DFA4DF-CED5-4BDD-8580-8EE8BFE240A2Q37704485-90D1C4DA-DB44-4B36-BE75-B58A3A586629Q37824455-0A07BFF0-5837-4CC5-ACCF-306853460156Q38653220-D723938A-B9B8-44F2-93DC-03676AB2922FQ38761708-B2DC70F0-109E-46D2-974A-61B9EFEB746EQ38856405-01A669CE-6158-4C7E-A897-95211841A52BQ38868221-BB6C615C-8C51-4EA3-B35A-C951F0016337Q38983572-3F25368C-2D1B-4DA5-A296-B94A8ED32158Q39033807-2AD4D3CE-98B9-4F3E-8CB6-9C75E40AB320Q39042842-16AE27DF-BD48-461A-ACD4-27983794E0BAQ39638383-B1E9455A-A9E2-47FC-8209-0037FF66078CQ40171647-F1A0DD75-A5F1-4037-96FB-A0B00CA665E4Q41860558-2A8A7C9B-9AA4-42C0-B7DA-F356F09F36B6Q44629514-71AFB8C1-790D-4B94-BCBE-7AC02A188E69Q44886501-97042960-19C4-495F-B776-E3D9239FA7E4Q45869420-96517C30-2A7C-4AE9-8242-F6C1C1AD13F1Q46109454-D09E94A6-9312-4E0D-B0F6-4F12A6722E04Q46756991-36B0A16B-35CE-4C7D-820E-F431483D2AA1Q46956296-BC2557A1-3EDC-472E-8D92-4962B7E403F4Q47161931-EC2122B0-4ED6-49C6-9333-382B64896665Q48239368-82F4DEE9-53D1-45A4-9643-16E72A49B1D6Q48293567-F1E3F42E-7E59-4D1F-A5F7-163614B20D35Q48772481-CA31565D-B191-41F3-9EB0-4C8A8C0877E8
P2860
Extramotor involvement in ALS: PET studies with the GABAA ligand [11C]flumazenil
description
im November 2000 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 November 2000
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2000
@uk
name
Extramotor involvement in ALS: PET studies with the GABAA ligand [11C]flumazenil
@en
Extramotor involvement in ALS: PET studies with the GABAA ligand [11C]flumazenil
@nl
type
label
Extramotor involvement in ALS: PET studies with the GABAA ligand [11C]flumazenil
@en
Extramotor involvement in ALS: PET studies with the GABAA ligand [11C]flumazenil
@nl
prefLabel
Extramotor involvement in ALS: PET studies with the GABAA ligand [11C]flumazenil
@en
Extramotor involvement in ALS: PET studies with the GABAA ligand [11C]flumazenil
@nl
P2860
P50
P356
P1433
P1476
Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil
@en
P2093
P2860
P304
P356
10.1093/BRAIN/123.11.2289
P407
P478
123 ( Pt 11)
P577
2000-11-01T00:00:00Z